B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals
This trial is active, not recruiting.
|Conditions||asplenia, β-thalassemia major|
|Sponsor||Aghia Sophia Children's Hospital of Athens|
|Start date||October 2010|
|End date||February 2012|
|Trial size||37 participants|
|Trial identifier||NCT01846923, 51657MoH|
The purpose of this study is to determine whether one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) induces immunological memory in asplenic adults and whether previously administered immunizations with the 23-valent polysaccharide pneumococcal vaccine influence the cellular immune response to PCV13 in this group.
|Intervention model||single group assignment|
immunoglobulin G (IgG) B memory cell response one month post vaccination (measured by ELISpot)
time frame: One month post-PCV13
immunoglobulin M (IgM) B memory cell response one month post vaccination (measured by ELISpot)
time frame: one month post PCV13
Maintenance of B memory cells three years after PCV13 vaccination
time frame: three years after study vaccination
Male or female participants from 18 years up to 60 years old.
Inclusion Criteria: - Asplenia - β-thalassemia major - older than 18 years Exclusion Criteria: - no previously recorded allergy to PCV - no intravenous immunoglobulin (IVIG) given within the previous 6 months - no other vaccine given within the previous 6 months
|Official title||Study of the B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With Beta-thalassemia Major|
Call for more information